Halozyme Therapeutics, Inc.
HALO
$48.29
-$1.94-3.86%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.08B | 1.02B | 947.36M | 873.30M | 862.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.08B | 1.02B | 947.36M | 873.30M | 862.99M |
| Cost of Revenue | 242.66M | 222.70M | 233.84M | 238.10M | 247.25M |
| Gross Profit | 841.65M | 792.63M | 713.52M | 635.21M | 615.74M |
| SG&A Expenses | 161.56M | 154.34M | 149.69M | 143.72M | 146.96M |
| Depreciation & Amortization | 71.05M | 71.05M | 71.05M | 71.13M | 71.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 486.84M | 463.85M | 470.35M | 468.71M | 481.18M |
| Operating Income | 597.47M | 551.48M | 477.01M | 404.59M | 381.81M |
| Income Before Tax | 604.93M | 557.13M | 480.09M | 416.71M | 392.12M |
| Income Tax Expenses | 119.57M | 113.04M | 87.63M | 79.41M | 73.32M |
| Earnings from Continuing Operations | 485.36 | 444.09 | 392.47 | 337.29 | 318.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 485.36M | 444.09M | 392.47M | 337.29M | 318.80M |
| EBIT | 597.47M | 551.48M | 477.01M | 404.59M | 381.81M |
| EBITDA | 673.22M | 627.09M | 553.00M | 480.80M | 458.42M |
| EPS Basic | 3.86 | 3.50 | 3.08 | 2.62 | 2.45 |
| Normalized Basic EPS | 2.98 | 2.72 | 2.33 | 1.95 | 1.81 |
| EPS Diluted | 3.76 | 3.43 | 3.02 | 2.58 | 2.42 |
| Normalized Diluted EPS | 2.92 | 2.67 | 2.29 | 1.92 | 1.79 |
| Average Basic Shares Outstanding | 503.59M | 507.31M | 509.96M | 515.08M | 519.69M |
| Average Diluted Shares Outstanding | 514.98M | 517.22M | 519.28M | 523.23M | 527.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |